Ratings by Morgan Stanley (Michael Ulz)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/25/2026 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2026 | Vir Biotechnology | VIR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/15/2025 | Kyverna Therapeutics Inc | KYTX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/4/2025 | Kyverna Therapeutics Inc | KYTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2025 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2025 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/24/2025 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/3/2025 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/6/2025 | Akero Therapeutics | AKRO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2025 | Y-mAbs Therapeutics | YMAB | Upgrade | Equalweight (Underweight) |
4.19 (8.61) |
105.49% | Details | |
| 7/30/2025 | Ionis Pharmaceuticals | IONS | Upgrade | Overweight (Equalweight) |
41.48 (74.04) |
78.5% | Details | |
| 7/15/2025 | Ionis Pharmaceuticals | IONS | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/12/2025 | Akero Therapeutics | AKRO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2025 | Silence Therapeutics | SLN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/1/2025 | Kyverna Therapeutics Inc | KYTX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/1/2025 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2025 | Vir Biotechnology | VIR | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2025 | Silence Therapeutics | SLN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2025 | Y-mAbs Therapeutics | YMAB | Maintain | Underweight (N/A) |
|
Details | ||
| 3/3/2025 | Akero Therapeutics | AKRO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/12/2025 | Third Harmonic Bio | THRD | Downgrade | Equalweight (Overweight) |
4.65 (5.38) |
15.7% | Details | |
| 1/27/2025 | Akero Therapeutics | AKRO | Maintain | Overweight (N/A) |
|
Details | ||
| 1/10/2025 | IGM Biosciences | IGMS | Downgrade | Underweight (Equalweight) |
6.80 (1.27) |
-81.32% | Details | |
| 1/9/2025 | Vir Biotechnology | VIR | Upgrade | Overweight (Equalweight) |
7.89 (9.55) |
21.04% | Details | |
| 10/11/2024 | Ionis Pharmaceuticals | IONS | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/1/2024 | IGM Biosciences | IGMS | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/14/2024 | IGM Biosciences | IGMS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2024 | Y-mAbs Therapeutics | YMAB | Maintain | Underweight (N/A) |
|
Details | ||
| 8/9/2024 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2024 | Third Harmonic Bio | THRD | Upgrade | Overweight (Equalweight) |
10.96 (4.65) |
-57.57% | Details | |
| 8/2/2024 | Ionis Pharmaceuticals | IONS | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/2/2024 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/28/2024 | Silence Therapeutics | SLN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/5/2024 | Vir Biotechnology | VIR | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/16/2024 | Third Harmonic Bio | THRD | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/13/2024 | Fate Therapeutics | FATE | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/3/2024 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/11/2024 | Alpine Immune Sciences | ALPN | Downgrade | Equalweight (Overweight) |
38.94 (64.97) |
66.85% | Details | |
| 3/19/2024 | Alpine Immune Sciences | ALPN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/14/2024 | Silence Therapeutics | SLN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/11/2024 | IGM Biosciences | IGMS | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/4/2024 | Akero Therapeutics | AKRO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2024 | Kyverna Therapeutics Inc | KYTX | New Coverage | Overweight (N/A) |
27.17 (8.10) |
-70.19% | Details | |
| 2/27/2024 | Fate Therapeutics | FATE | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/22/2023 | Allovir Inc. | ALVR | Downgrade | Equalweight (Overweight) |
2.33 (9.81) |
321.03% | Details | |
| 11/28/2023 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2023 | IGM Biosciences | IGMS | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/13/2023 | Fate Therapeutics | FATE | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/8/2023 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2023 | Vir Biotechnology | VIR | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/6/2023 | Vir Biotechnology | VIR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2023 | Ionis Pharmaceuticals | IONS | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/3/2023 | Ionis Pharmaceuticals | IONS | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/3/2023 | Alpine Immune Sciences | ALPN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2023 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2023 | Akero Therapeutics | AKRO | Maintain | Overweight (N/A) |
|
Details | ||
| 9/27/2023 | Ionis Pharmaceuticals | IONS | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/14/2023 | Y-mAbs Therapeutics | YMAB | Maintain | Underweight (N/A) |
|
Details | ||
| 8/11/2023 | Third Harmonic Bio | THRD | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/10/2023 | Fate Therapeutics | FATE | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/9/2023 | Mirati Therapeutics | MRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/7/2023 | Karyopharm Therapeutics | KPTI | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/7/2023 | IGM Biosciences | IGMS | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/3/2023 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/20/2023 | Vir Biotechnology | VIR | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/14/2023 | Mirati Therapeutics | MRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/12/2023 | Akero Therapeutics | AKRO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2023 | Y-mAbs Therapeutics | YMAB | Maintain | Underweight (N/A) |
|
Details | ||
| 5/10/2023 | Mirati Therapeutics | MRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/8/2023 | Silence Therapeutics | SLN | New Coverage | Overweight (N/A) |
6.18 (6.23) |
0.81% | Details | |
| 5/5/2023 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/24/2023 | Iveric Bio | ISEE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/11/2023 | Ionis Pharmaceuticals | IONS | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/24/2023 | Senti Biosciences, Inc. | SNTI | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/27/2023 | Mirati Therapeutics | MRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/27/2023 | Allakos Inc. | ALLK | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/27/2023 | Senti Biosciences, Inc. | SNTI | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/27/2023 | Xilio Therapeutics Inc | XLO | Maintain | Overweight (N/A) |
|
Details | ||
| 1/27/2023 | Karyopharm Therapeutics | KPTI | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/27/2023 | Allovir Inc. | ALVR | Maintain | Overweight (N/A) |
|
Details | ||
| 1/27/2023 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/27/2023 | Y-mAbs Therapeutics | YMAB | Downgrade | Underweight (Equalweight) |
4.73 (4.19) |
-11.42% | Details | |
| 1/27/2023 | Cabaletta Bio Inc. | CABA | Upgrade | Overweight (Equalweight) |
11.12 (3.17) |
-71.49% | Details | |
| 1/27/2023 | Vir Biotechnology | VIR | Upgrade | Equalweight (Underweight) |
30.84 (7.89) |
-74.42% | Details | |
| 1/27/2023 | Akero Therapeutics | AKRO | Upgrade | Overweight (Equalweight) |
48.82 (54.74) |
12.13% | Details | |
| 1/19/2023 | Alpine Immune Sciences | ALPN | New Coverage | Overweight (N/A) |
8.59 (64.97) |
656.34% | Details | |
| 1/6/2023 | Fate Therapeutics | FATE | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/21/2022 | Ionis Pharmaceuticals | IONS | Downgrade | Equalweight (Overweight) |
37.96 (41.48) |
9.27% | Details | |
| 12/19/2022 | Akero Therapeutics | AKRO | Maintain | Overweight (N/A) |
|
Details | ||
| 12/15/2022 | Third Harmonic Bio | THRD | Downgrade | Equalweight (Overweight) |
19.80 (10.96) |
-44.65% | Details | |
| 12/13/2022 | Mirati Therapeutics | MRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/6/2022 | Mirati Therapeutics | MRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/31/2022 | Y-mAbs Therapeutics | YMAB | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/10/2022 | Third Harmonic Bio | THRD | New Coverage | Overweight (N/A) |
20.01 (19.80) |
-1.05% | Details | |
| 10/7/2022 | Senti Biosciences, Inc. | SNTI | New Coverage | Equalweight (N/A) |
5.28 (0.96) |
-81.82% | Details | |
| 9/9/2022 | Allakos Inc. | ALLK | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2022 | Y-mAbs Therapeutics | YMAB | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2022 | Karyopharm Therapeutics | KPTI | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2022 | Fate Therapeutics | FATE | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2022 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2022 | Allovir Inc. | ALVR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/30/2022 | Cabaletta Bio Inc. | CABA | Downgrade | Equalweight (Overweight) |
1.90 (3.17) |
66.84% | Details | |
| 7/7/2022 | Iveric Bio | ISEE | Maintain | Overweight (N/A) |
|
Details | ||
| 6/14/2022 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/5/2022 | Fate Therapeutics | FATE | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/5/2022 | Mirati Therapeutics | MRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/1/2022 | Mirati Therapeutics | MRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/22/2022 | Karyopharm Therapeutics | KPTI | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/7/2022 | Iveric Bio | ISEE | New Coverage | Overweight (N/A) |
13.63 (39.95) |
193.1% | Details | |
| 2/1/2022 | Freeline | FRLN | Downgrade | Equalweight (Overweight) |
1.18 (6.48) |
449.15% | Details | |
| 1/5/2022 | Avrobio Inc. | AVRO | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/22/2021 | Allakos Inc. | ALLK | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/13/2021 | IGM Biosciences | IGMS | Downgrade | Equalweight (Overweight) |
49.84 (1.27) |
-97.45% | Details | |
| 11/19/2021 | Blueprint Medicines | BPMC | New Coverage | Equalweight (N/A) |
111.99 (89.59) |
-20% | Details | |
| 11/19/2021 | Karyopharm Therapeutics | KPTI | Downgrade | Equalweight (Overweight) |
8.29 (8.77) |
5.79% | Details | |
| 11/19/2021 | Avrobio Inc. | AVRO | Downgrade | Equalweight (Overweight) |
4.85 (1.40) |
-71.13% | Details | |
| 11/19/2021 | Y-mAbs Therapeutics | YMAB | New Coverage | Equalweight (N/A) |
19.03 (8.61) |
-54.76% | Details | |
| 11/16/2021 | Xilio Therapeutics Inc | XLO | New Coverage | Overweight (N/A) |
22.16 (0.53) |
-97.61% | Details | |
| 11/10/2021 | Allakos Inc. | ALLK | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/9/2021 | Mirati Therapeutics | MRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/5/2021 | Fate Therapeutics | FATE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/19/2021 | Cabaletta Bio Inc. | CABA | New Coverage | Overweight (N/A) |
12.74 (3.17) |
-75.12% | Details | |
| 10/19/2021 | Allovir Inc. | ALVR | New Coverage | Overweight (N/A) |
20.92 (9.81) |
-53.11% | Details | |
| 10/19/2021 | Akero Therapeutics | AKRO | Downgrade | Equalweight (Overweight) |
21.34 (54.74) |
156.51% | Details | |
| 9/21/2021 | Mirati Therapeutics | MRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/26/2021 | Mirati Therapeutics | MRTX | New Coverage | Equalweight (N/A) |
147.89 (58.70) |
-60.31% | Details | |
| 8/26/2021 | Fate Therapeutics | FATE | New Coverage | Equalweight (N/A) |
71.53 (1.33) |
-98.14% | Details | |
| 8/26/2021 | IGM Biosciences | IGMS | New Coverage | Overweight (N/A) |
73.72 (49.84) |
-32.39% | Details | |
| 8/26/2021 | Allakos Inc. | ALLK | New Coverage | Equalweight (N/A) |
83.39 (0.33) |
-99.6% | Details |
